Table 4.

EC₅₀ values for deleobuvir at baseline for amplicons with and without mutations at codons 421 and 499

Amplicon variant	n	EC50 (nM)
		Geometric mean	Range	Fold changed
GT1a, wild-type A421	27	22	1.2–118
GT1a, A421V	3a	127	115–150	5.8
GT1b, wild-type V499	28	4.3	0.4–31
GT1b, V499 variantsb	12c	24	6.7–98	5.6
GT1a, wild-type A499	29	27	1.2–153
GT1a, A499T	1	7.8	±1.5	0.3

^aExcluding 1 patient (deleobuvir at 400 mg) whose sample did not replicate in vitro and whose EC₅₀ therefore could not be obtained.

^bThe V499 variants included 6 V499A, 5 V499T, and 1 V499I.

^cExcluding 1 patient (deleobuvir at 200 mg) whose sample did not replicate in vitro and whose EC₅₀ therefore could not be obtained. One GT1b patient (placebo) who had mutations A421V plus V499A at baseline but whose sample did replicate in vitro and whose EC₅₀ therefore could not be obtained is excluded.

^dWilcoxon rank-sum test for equality of mean baseline EC₅₀ values for wild type compared to variant: P = 0.002, 0.0001, and 0.3 for the data in rows 2, 4, and 6, respectively.